Search research articles
Contact Us
Filters
Showing results (1-10 of 186) with videos related to
Page
of 19
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
November 1, 2011
Letter to the Editor on: A. Siegmann et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival. Results of a retrospective study. In: Strahlenther Onkol 2011;187:467-72 (No. 8) (DOI 10.1007/s00066-011-2229-3). P. Ghadjar, D. Zwahlen, D.M. Aebersold: Selection bias is not a good reason for dose intensification in patients with PSA recurrence after radical prostatectomy
Pirus Ghadjar
European Urology
|
November 13, 2024
Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Randomised Trial
Pirus Ghadjar, Daniel Zips
European Urology
|
March 2, 2016
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30
Piet Ost, Pirus Ghadjar
European Urology
|
November 21, 2019
Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9
Pirus Ghadjar, Thomas Wiegel
Nature Reviews. Urology
|
May 17, 2018
Optimizing radiotherapy for intermediate-risk localized disease
Pirus Ghadjar, Thomas Wiegel
European Urology
|
February 22, 2021
Re: Timing of Radiotherapy After Radical Prostatectomy (RadicalS-RT): A Randomised, Controlled Phase 3 Trial
Pirus Ghadjar, Thomas Wiegel
European Urology
|
January 24, 2019
Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31
Pirus Ghadjar, Thomas Wiegel
The Lancet. Oncology
|
January 8, 2020
Androgen deprivation therapy plus salvage radiotherapy after prostatectomy
Pirus Ghadjar, Thomas Wiegel
European Urology
|
October 24, 2017
Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 2018;73:156-65
Pirus Ghadjar, Thomas Wiegel
European Urology
|
December 16, 2011
Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51
Pirus Ghadjar, Daniel M Aebersold
Page
of 19
Search research articles
Search
Showing results (1-10 of 186) with videos related to
Sort By:
Page
of 19
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
November 1, 2011
Letter to the Editor on: A. Siegmann et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival. Results of a retrospective study. In: Strahlenther Onkol 2011;187:467-72 (No. 8) (DOI 10.1007/s00066-011-2229-3). P. Ghadjar, D. Zwahlen, D.M. Aebersold: Selection bias is not a good reason for dose intensification in patients with PSA recurrence after radical prostatectomy
Pirus Ghadjar
European Urology
|
November 13, 2024
Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Randomised Trial
Pirus Ghadjar, Daniel Zips
European Urology
|
March 2, 2016
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30
Piet Ost, Pirus Ghadjar
European Urology
|
November 21, 2019
Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9
Pirus Ghadjar, Thomas Wiegel
Nature Reviews. Urology
|
May 17, 2018
Optimizing radiotherapy for intermediate-risk localized disease
Pirus Ghadjar, Thomas Wiegel
European Urology
|
February 22, 2021
Re: Timing of Radiotherapy After Radical Prostatectomy (RadicalS-RT): A Randomised, Controlled Phase 3 Trial
Pirus Ghadjar, Thomas Wiegel
European Urology
|
January 24, 2019
Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31
Pirus Ghadjar, Thomas Wiegel
The Lancet. Oncology
|
January 8, 2020
Androgen deprivation therapy plus salvage radiotherapy after prostatectomy
Pirus Ghadjar, Thomas Wiegel
European Urology
|
October 24, 2017
Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 2018;73:156-65
Pirus Ghadjar, Thomas Wiegel
European Urology
|
December 16, 2011
Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51
Pirus Ghadjar, Daniel M Aebersold
Page
of 19